Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Previously Treated With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects With X-Linked Retinitis Pigmentosa Previously Treated With Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study

NCT03584165 is registered in ClinicalTrials.gov with NightstaRx Ltd, a Biogen Company as lead sponsor.

NCT NCT03584165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03584165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects With Choroideremia Previously Treated With Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects With X-Linked Retinitis Pigmentosa Previously Treated With Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study
Lead sponsor
NightstaRx Ltd, a Biogen Company
Phase
Phase 3
Overall status
Completed
Start date
June 4, 2018
Completion date
June 22, 2026
Enrollment
277 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

choroideremia, x-linked retinitis pigmentosa